Lupin receives approval from USFDA for Brexpiprazole Tablets
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
“One Earth, One Health” vision can become a reality only with active global collaboration where countries don’t think of only themselves, but of collective global outcomes
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Proposed combination enhances Pfizer’s position as a leading company in oncology
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
The inspection concluded with no observations
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Subscribe To Our Newsletter & Stay Updated